---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115317"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:32:45.244932+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q3 2024: revenue $19.0M (+26% YoY), net loss $10.4M; reaffirms FY2024 guidance

## Summary
- Revenue $19.0M, +26% YoY; OviTex unit sales +39%, OviTex PRS +44% YoY.
- Net loss $10.4M vs $11.0M loss in Q3 2023; operating loss $9.4M vs $10.2M.
- Gross margin 68% vs 69% YoY due to higher excess/obsolete inventory charge.
- Closed public offering yielding ~$46M gross proceeds; cash $17.3M at Sept 30.
- Expects $5M-$10M reduction in 2025 operating expenses from H1 2024 annualized; reiterates FY2024 revenue guidance $74.5M-$76.5M.

## SEC filing metadata
- accession: 0001104659-24-115317
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465924115317/0001104659-24-115317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465924115317/tm2427737d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115317
- JSON: https://secwatch.observer/filing/0001104659-24-115317.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.